Back to search

Peptide record

TPDB24269

DIM-LF11-322 Antibacterial Anticancer Toxicity standard
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB24269
DIM-LF11-322
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia CancerPPD 2.0
standard
No
A 18-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia and CancerPPD 2.0, with an available 3D structural model.
Sequence
PFWRIRIRRPFWRIRIRR
Physicochemical Analysis
C122H194N44O19
ANDCEQGHLKMSTYV
R
2581.17
13.25
8
0
8
+8
0.18
-0.967
86.67
Mammalian: >20 hour Yeast: >20 hour E.coli: ?
11000
426.16
0
Residue Composition
number
0
A
8
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
4
I
0
L
0
K
0
M
2
F
2
P
0
S
0
T
2
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 8 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 4 L: 0 K: 0 M: 0 F: 2 P: 2 S: 0 T: 0 W: 2 Y: 0 V: 0
Chemical Descriptors
18
C122H194N44O19
2581.17
13.25
+8
0.18
-0.967
Free
L
Linear
Free
Anticancer
Synthetic
Evidence Records 6 records
Evidence 1 Activity

Activity

LC50
LC50 = 6.3 ± 0.3 µM
Anticancer
6.3

Target

Skin Cancer
A-375
Skin

Assay & Model

MTS assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
EP_2943215_B1

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

LC50
LC50 < 1 ± 0.0 µM
Anticancer
1

Target

Skin Cancer
SBcl2
Skin

Assay & Model

MTS assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
EP_2943215_B1
Evidence 3 Activity

Activity

LC50
LC50 = 4.6 ± 0.1 µM
Anticancer
4.6

Target

Skin Cancer
WM164
Skin

Assay & Model

MTS assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
EP_2943215_B1
Evidence 4 Activity

Activity

LC50
Toxicity
84.7±3.4 µM
Cytotoxic
LC50 | 84.7±3.4 | µM | target cell: Human dermal fibroblasts

Target

Human dermal fibroblasts

Source & Reference

NA
DBAASP
Design of human lactoferricin derived antitumor peptides-activity and specificity against malignant melanoma in 2D and 3D model studies. | Biochim Biophys Acta | 2020
Evidence 5 Activity

Activity

LC50
Toxicity
52.5±4.3 µM
Cytotoxic
LC50 | 52.5±4.3 | µM | target cell: Human epidermal melanocytes

Target

Human epidermal melanocytes

Source & Reference

NA
DBAASP
Design of human lactoferricin derived antitumor peptides-activity and specificity against malignant melanoma in 2D and 3D model studies. | Biochim Biophys Acta | 2020
Evidence 6 Activity

Activity

Toxicity
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: Not available

Target

erythrocytes

Source & Reference

NA
DRAMP
Biochim Biophys Acta Biomembr. 2020 Aug 1 1862(8):183265.